Table 2 Long-term effect of haart a use on herpes zoster incidence
Variable | Univariate | Multivariate1 | Multivariate2 | Multivariate3 |
|---|---|---|---|---|
HRb(CIc) | HR (CI) | HR (CI) | HR (CI) | |
HAART use group: | ||||
No | 1.00 | |||
Yes | 0.72(0.48–1.09) | |||
HAART use adherence since last visit c | ||||
>95% | 0.54*(0.31–0.94) | 0.56*(0.32–0.99) | 0.61(0.33–1.11) | 0.76(0.41–1.38) |
75%–95% | 0.32(0.09–1.05) | 0.31(0.09–1.03) | 0.30(0.09–1.03) | 0.34(0.10–1.14) |
0 < adherence <75% | 1.70(0.70–4.14) | 1.38(0.53–3.63) | 1.25(0.46–3.41) | 1.23(0.46–3.31) |
HAART users, but did not use HAART since last visit | 0.95(0.52–1.72) | 0.87(0.47–1.62) | 0.77(0.39–1.52) | 0.65(0.33–1.27) |
No HAART users | 1.00 | 1.00 | 1.00 | 1.00 |
Current CD4+ cell counts (per100 cell increase) d | 0.85***(0.77–0.93) | 0.86***(0.78–0.94) | ||
Current CD8+ cell counts (per 100 cell increase) d | 0.96(0.90–1.01) | |||
HIV viral load (per Log 10) d | 1.55***(1.30–1.84) | 1.59***(1.31–1.93) | ||
Quality of life score d | 0.98**(0.97–0.99) | 0.99*(0.98–0.99) | 0.98*(0.97–0.99) | 0.98*(0.97–0.99) |
Used acyclovir since last visitd: | ||||
No | 1.00 | 1.00 | 1.00 | 1.00 |
Yes | 1.88*(1.04–3.18) | 1.68(0.88–3.22) | 1.52(0.75–3.10) | 1.56(0.79–3.08) |